| Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients F Massa, M Cremoni, A Gérard, H Grabsi, L Rogier, M Blois, C Couzin, ... EBioMedicine 73, 2021 | 77 | 2021 |
| Functional exhaustion of type I and II interferons production in severe COVID-19 patients C Ruetsch, V Brglez, M Cremoni, K Zorzi, C Fernandez, S Boyer-Suavet, ... Frontiers in medicine 7, 603961, 2021 | 44 | 2021 |
| Th17-Immune response in patients with membranous nephropathy is associated with thrombosis and relapses M Cremoni, V Brglez, S Perez, F Decoupigny, K Zorzi, M Andreani, ... Frontiers in immunology 11, 574997, 2020 | 43 | 2020 |
| Rituximab bioavailability in primary membranous nephropathy S Boyer-Suavet, M Andreani, M Cremoni, V Brglez, S Benzaken, ... Nephrology Dialysis Transplantation 34 (8), 1423-1425, 2019 | 36 | 2019 |
| Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy M Teisseyre, M Cremoni, S Boyer-Suavet, C Ruetsch, D Graça, ... Frontiers in Immunology 13, 859419, 2022 | 23 | 2022 |
| Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy M Teisseyre, S Boyer-Suavet, M Crémoni, V Brglez, V Esnault, ... Kidney International Reports 6 (4), 1183-1188, 2021 | 19 | 2021 |
| Risk factors associated with immune checkpoint inhibitor–induced acute kidney injury compared with other immune-related adverse events: a case–control study AO Gérard, S Barbosa, N Parassol, M Andreani, D Merino, M Cremoni, ... Clinical Kidney Journal 15 (10), 1881-1887, 2022 | 17 | 2022 |
| Rituximab immunomonitoring predicts remission in membranous nephropathy M Teisseyre, M Cremoni, S Boyer-Suavet, T Crepin, S Benzaken, K Zorzi, ... Frontiers in Immunology 12, 738788, 2021 | 15 | 2021 |
| Low baseline IFN-γ response could predict hospitalization in COVID-19 patients M Cremoni, J Allouche, D Graca, K Zorzi, C Fernandez, M Teisseyre, ... Frontiers in immunology 13, 953502, 2022 | 14 | 2022 |
| Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. EBioMedicine. 2021; 73: 103679 F Massa, M Cremoni, A Gérard, H Grabsi, L Rogier, M Blois, C Couzin, ... J. EBIOM, 2021 | 13 | 2021 |
| Functional immune assay using interferon-gamma could predict infectious events in end-stage kidney disease S Boyer-Suavet, M Cremoni, T Dupeyrat, K Zorzi, V Brglez, S Benzaken, ... Clinica Chimica Acta 502, 287-292, 2020 | 12 | 2020 |
| Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients A Gérard, J Doyen, M Cremoni, L Bailly, K Zorzi, C Ruetsch-Chelli, ... Journal for Immunotherapy of Cancer 9 (6), 2021 | 11 | 2021 |
| Toxic occupational exposures and membranous nephropathy M Cremoni, S Agbekodo, M Teisseyre, K Zorzi, V Brglez, S Benzaken, ... Clinical Journal of the American Society of Nephrology 17 (11), 1609-1619, 2022 | 9 | 2022 |
| Humoral and cellular response of frontline health care workers infected by SARS-CoV-2 in Nice, France: a prospective single-center cohort study M Cremoni, C Ruetsch, K Zorzi, C Fernandez, S Boyer-Suavet, ... Frontiers in Medicine 7, 608804, 2021 | 8 | 2021 |
| Social Science Research Network F Massa, M Cremoni, A Gerard, H Grabsi, L Rogier, M Blois Rochester, NY, 2021 | 8 | 2021 |
| Optimization of rituximab Therapy in Adult patients with PLA2R1-associated Membranous Nephropathy with Artificial Intelligence A Destere, M Teisseyre, D Merino, M Cremoni, AO Gérard, T Crepin, ... Kidney International Reports 9 (1), 134-144, 2024 | 5 | 2024 |
| Both humoral and cellular immune responses to SARS-CoV-2 are essential to prevent infection: a prospective study in a working vaccinated population from Southern France D Graça, V Brglez, J Allouche, K Zorzi, C Fernandez, M Teisseyre, ... Journal of Clinical Immunology 43 (8), 1724-1739, 2023 | 5 | 2023 |
| Air pollution exposure induces a decrease in type II interferon response: a paired cohort study J Allouche, M Cremoni, V Brglez, D Graça, S Benzaken, K Zorzi, ... EBioMedicine 85, 2022 | 5 | 2022 |
| Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy M Teisseyre, V Brglez, M Cremoni, C Fernandez, D Graça, ... Clinical Journal of the American Society of Nephrology 18 (6), 785-787, 2023 | 3 | 2023 |
| Overcoming barriers to widespread use of CAR‐Treg therapy in organ transplant recipients M Cremoni, F Massa, A Sicard Hla 99 (6), 565-572, 2022 | 3 | 2022 |
